文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

生殖支原体感染可包含氟喹诺酮敏感与耐药菌株混合

Mycoplasma genitalium infections can comprise a mixture of both fluoroquinolone-susceptible and fluoroquinolone-resistant strains.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究针对澳大利亚生殖支原体感染,因Sanger测序未能检出耐药突变而怀疑存在低载量混合感染,采用三种额外PCR方法检测parC基因83和87位氨基酸耐药突变。结果显示最多27/423份样本(6.4%)存在敏感与耐药菌株混合,Sanger测序最多漏检3.8%(16/423)样本的氟喹诺酮耐药。混合感染可能影响临床管理,需改进耐药检测。

要点

  • 生殖支原体感染可混合存在氟喹诺酮敏感与耐药菌株。
  • Sanger测序可能漏检低载量混合感染中的耐药株。
  • 混合感染对临床用药选择和治疗失败有重要影响。

核心结论

  • 生殖支原体感染中可检出氟喹诺酮敏感与耐药菌株混合,混合感染可能影响患者管理并强调适当检测耐药和选择抗菌药物的重要性。

研究设计与样本

  • 研究采用三种额外PCR方法(等位基因特异性引物PCR、探针PCR和扩增子深度测序)检测parC基因83和87位氨基酸氟喹诺酮耐药突变,并与Sanger测序比较,共分析423份样本。

主要发现

  • 最多27/423份样本(6.4%)显示氟喹诺酮敏感与耐药菌株混合。
  • 其中1份样本被Sanger测序和所有三种额外PCR方法均提示混合。
  • 6份样本被两种或以上额外PCR方法检出但Sanger测序未检出。
  • 20份样本仅被一种额外PCR方法检出。
  • Sanger测序最多漏检3.8%(16/423)样本的氟喹诺酮耐药。

临床怎么用

  • 临床应意识到生殖支原体感染可能存在混合耐药株,Sanger测序阴性不能完全排除耐药。
  • 对氟喹诺酮治疗失败者,可考虑采用更敏感的PCR方法检测parC耐药突变以指导用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycoplasma genitalium was recently added to the CDC's antimicrobial resistance threats 'watch list', as it has rapidly become resistant to mainstay treatments. In Australia, treatment failure with fluoroquinolones remain commonplace, even when Sanger sequencing fails to identify evidence of resistance mutations. METHODS: Suspecting that Sanger sequencing may miss low-load mixed infections, we applied three additional PCR-based approaches (allele-specific primer-based PCR, probe-based PCR and amplicon deep sequencing) to detect mutations associated with fluoroquinolone susceptibility/resistance. We focused on resistance mutations at amino acid positions 83 and 87 of parC, as these were previously shown to be common in Australia. RESULTS: Our results showed evidence of mixtures of fluoroquinolone-susceptible and -resistant strains in up to 27/423 samples (6.4%). These included 1 sample that was indicated to be mixed by Sanger sequencing and all three additional PCR methods, 6 samples detected by two or more of the additional PCRs but not by Sanger sequencing and finally 20 samples that were detected by only one of the additional PCR methods. A key question was whether Sanger sequencing failed to detect fluoroquinolone resistance in any samples; overall, we observed that Sanger sequencing failed to detect fluoroquinolone resistance in up to 3.8% (16/423) of samples. CONCLUSIONS: The presence of mixed susceptibility infections may have important implications for clinical patient management and stresses the need for appropriate detection of resistance and selection of antimicrobials to ensure appropriate treatment of M. genitalium infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sweeney EL, Lowry K, Bletchly C, et al. Mycoplasma genitalium infections can comprise a mixture of both fluoroquinolone-susceptible and fluoroquinolone-resistant strains. J Antimicrob Chemother. 2021. PMID: 33448305. doi:10.1093/jac/dkaa542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。